Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mitomycin
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : UroGen Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
UroGen Pharma Announces License and Supply Agreement with Neopharm
Details : Neopharm will lead the regulatory process in Israel, which is supported by the results from the Phase 3 OLYMPUS trial that showed Jelmyto achieved clinically significant disease eradication in adults with LG-UTUC.
Brand Name : Jelmyto
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 28, 2021
Lead Product(s) : Mitomycin
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : UroGen Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?